Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Published on Aug 7, 2019in Science Translational Medicine17.992
· DOI :10.1126/SCITRANSLMED.AAX7392
Bradon R. McDonald17
Estimated H-index: 17
(TGen: Translational Genomics Research Institute),
Tania Contente-Cuomo12
Estimated H-index: 12
(TGen: Translational Genomics Research Institute)
+ 17 AuthorsMuhammed Murtaza20
Estimated H-index: 20
(TGen: Translational Genomics Research Institute)
Sources
Abstract
Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity for residual disease detection during or after completion of treatment in patients with nonmetastatic cancer. To address this gap and to improve sensitivity for minute quantities of residual tumor DNA in plasma, we have developed targeted digital sequencing (TARDIS) for multiplexed analysis of patient-specific cancer mutations. In reference samples, by simultaneously analyzing 8 to 16 known mutations, TARDIS achieved 91 and 53% sensitivity at mutant allele fractions (AFs) of 3 in 104 and 3 in 105, respectively, with 96% specificity, using input DNA equivalent to a single tube of blood. We successfully analyzed up to 115 mutations per patient in 80 plasma samples from 33 women with stage I to III breast cancer. Before treatment, TARDIS detected ctDNA in all patients with 0.11% median AF. After completion of neoadjuvant therapy, ctDNA concentrations were lower in patients who achieved pathological complete response (pathCR) compared to patients with residual disease (median AFs, 0.003 and 0.017%, respectively, P = 0.0057, AUC = 0.83). In addition, patients with pathCR showed a larger decrease in ctDNA concentrations during neoadjuvant therapy. These results demonstrate high accuracy for assessment of molecular response and residual disease during neoadjuvant therapy using ctDNA analysis. TARDIS has achieved up to 100-fold improvement beyond the current limit of ctDNA detection using clinically relevant blood volumes, demonstrating that personalized ctDNA tracking could enable individualized clinical management of patients with cancer treated with curative intent.
Figures & Tables
Download
đź“– Papers frequently viewed together
References45
Newest
#1Françoise Rothé (ULB: Université libre de Bruxelles)H-Index: 31
#2Maria Joao Silva (Peter MacCallum Cancer Centre)H-Index: 7
Last. Michail Ignatiadis (ULB: Université libre de Bruxelles)H-Index: 46
view all 23 authors...
Purpose: In the neoadjuvant treatment (NAT) setting, dual HER2-targeted therapy is associated with increased pathologic complete response (pCR) rates compared with each therapy alone. Biomarkers allowing to predict treatment response during NAT are needed. We aim to evaluate whether circulating tumor DNA (ctDNA) is associated with response to anti-HER2–targeted therapy. Experimental Design: Plasma DNA collected before NAT, at week 2, and before surgery from patients enrolled in the NeoALTTO tria...
Source
#1Jeanne Tie (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 28
#2Joshua D. Cohen (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 17
Last. Peter Gibbs (WEHI: Walter and Eliza Hall Institute of Medical Research)H-Index: 61
view all 34 authors...
Objective For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC. Design We enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4–10 weeks after surgery. Somatic mutations in individual ...
Source
#1Tim Butler (OHSU: Oregon Health & Science University)H-Index: 58
: Pathological complete response (pCR) is an accurate predictor of good outcome following neoadjuvant chemotherapy (NAC) for locally advanced breast cancer. The presence of circulating-tumor DNA (ctDNA) has recently been reported to be strongly predictive of poor outcome in similar patient groups. We monitored ctDNA levels from 10 women undergoing NAC for locally advanced breast cancer using a patient-specific, hybrid-capture sequencing technique sensitive to the level of one altered allele in 1...
Source
#1Valsamo Anagnostou (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 35
#2Patrick M. Forde (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 35
Last. Samuel Rosner (JHBMC: Johns Hopkins Bayview Medical Center)H-Index: 6
view all 36 authors...
Despite the initial successes of immunotherapy, there is an urgent clinical need for molecular assays that identify patients more likely to respond. Here, we report that ultrasensitive measures of circulating tumor DNA (ctDNA) and T-cell expansion can be used to assess responses to immune checkpoint blockade in metastatic lung cancer patients ( N = 24). Patients with clinical response to therapy had a complete reduction in ctDNA levels after initiation of therapy, whereas nonresponders had no si...
Source
#1Mjm Magbanua (UCSF: University of California, San Francisco)H-Index: 1
#2L Brown-Swigart (Natera)H-Index: 1
Last. L.J. van 't VeerH-Index: 40
view all 29 authors...
ctDNA analysis offers a non-invasive approach for monitoring response and resistance to treatment. Serial ctDNA testing during neoadjuvant therapy (NAT) may provide early indicators of emerging resistance and disease progression. In this study, we analyzed ctDNA from high-risk early breast cancer patients who received NAT and definitive surgery in the I-SPY 2 TRIAL (NCT01042379). We hypothesize that (1) assessment of ctDNA levels early in treatment will improve the performance of molecular and i...
Source
#1Asaf ZviranH-Index: 11
#2Steven T. K. Hill (Cornell University)H-Index: 2
Last. Dan A. Landau (Cornell University)H-Index: 25
view all 22 authors...
Solid malignancies are often diagnosed at a late stage with dismal prognosis. Even after cancer is diagnosed, we lack sensitive tools to guide difficult therapeutic decisions such as adjuvant therapy. Sensitive cancer detection by blood biopsy can therefore transform care by enabling early detection and residual disease monitoring. Cell free DNA mutation detection has shown significant promise in its ability to survey the somatic genome and enable detection of cancer mutations in the peripheral ...
Source
#1Joseph A. Sparano (Yeshiva University)H-Index: 85
#2Robert Gray (Harvard University)H-Index: 64
Last. John A. Olson (Yeshiva University)H-Index: 3
view all 30 authors...
Abstract Background The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score. Methods We performed a prospective trial involving 10,273 women with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary node–negative breast cancer...
Source
#1Havell Markus (TGen: Translational Genomics Research Institute)H-Index: 3
#2Tania Contente-Cuomo (TGen: Translational Genomics Research Institute)H-Index: 12
Last. Muhammed Murtaza (TGen: Translational Genomics Research Institute)H-Index: 20
view all 16 authors...
Pre-analytical factors can significantly affect circulating cell-free DNA (cfDNA) analysis. However, there are few robust methods to rapidly assess sample quality and the impact of pre-analytical processing. To address this gap and to evaluate effects of DNA extraction methods and blood collection tubes on cfDNA yield and fragment size, we developed a multiplexed droplet digital PCR (ddPCR) assay with 5 short and 4 long amplicons targeting single copy genomic loci. Using this assay, we compared ...
Source
#1Steven J. Katz (UM: University of Michigan)H-Index: 76
#2Reshma Jagsi (UM: University of Michigan)H-Index: 79
Last. Monica Morrow (Cornell University)H-Index: 107
view all 3 authors...
Source
#1Joshua D. CohenH-Index: 17
#2Lu Li (Johns Hopkins University)H-Index: 13
Last. Austin MattoxH-Index: 7
view all 42 authors...
Earlier detection is key to reducing cancer deaths. Here we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities rang...
Source
Cited By74
Newest
#1Shuo Li (UCLA: University of California, Los Angeles)H-Index: 1
#2Weihua Zeng (UCLA: University of California, Los Angeles)H-Index: 1
Last. Xianghong Jasmine Zhou (UCLA: University of California, Los Angeles)H-Index: 32
view all 13 authors...
PurposeCell-free DNA (cfDNA) offers a non-invasive approach to monitor cancer. Here we develop a method using whole-exome sequencing (WES) of cfDNA for simultaneously monitoring the full spectrum of cancer treatment outcomes, including MRD, recurrence, evolution, and second primary cancer. null Experimental DesignThree simulation datasets were generated from 26 cancer patients to benchmark the detection performance of MRD/recurrence and second primary cancers. For further validation, cfDNA sampl...
Source
#1Mahendra Naidoo (Peter MacCallum Cancer Centre)H-Index: 1
#2Oliver Piercey (Peter MacCallum Cancer Centre)H-Index: 1
Last. Jeanne Tie (Peter MacCallum Cancer Centre)H-Index: 28
view all 3 authors...
PURPOSE OF REVIEW Improving outcomes for patients with colorectal cancer in both the adjuvant and metastatic setting has been challenging. Here, we review the current and future directions for using ctDNA in clinical practice. RECENT FINDINGS Circulating tumour DNA (ctDNA) with its ability to detect minimal residual disease is beginning to refine the way we assess recurrence risk in the adjuvant setting. We can potentially tailor treatments to reduce recurrence risk and minimize treatment toxici...
Source
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies ...
Source
#1Silvia Waldeck (DKFZ: German Cancer Research Center)H-Index: 2
#2Jan Mitschke (University of Freiburg)H-Index: 8
Last. Nikolas von Bubnoff (DKFZ: German Cancer Research Center)H-Index: 21
view all 27 authors...
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non-small-cell lung cancer (NSCLC). However, little is known about its dynamics during and after tumor resection, or its potential for predicting clinical outcomes. Here, we applied a targeted-capture high-throughput sequencing approach to profile ctDNA at various disease milestones and assessed its predictive value in pat...
Source
#1N. Honoré (UCL: Université catholique de Louvain)
#2R. Galot (UCL: Université catholique de Louvain)H-Index: 1
One reason why some patients experience recurrent disease after a curative-intent treatment might be the persistence of residual tumor cells, called minimal residual disease (MRD). MRD cannot be identified by standard radiological exams or clinical evaluation. Tumor-specific alterations found in the blood indirectly diagnose the presence of MRD. Liquid biopsies thus have the potential to detect MRD, allowing, among other things, the detection of circulating tumor DNA (ctDNA), circulating tumor c...
Source
#1M.K. Thompson (Cambridge University Hospitals NHS Foundation Trust)H-Index: 1
#2Davina Gale (University of Cambridge)H-Index: 17
Last. James D. Brenton (Cambridge University Hospitals NHS Foundation Trust)H-Index: 66
view all 3 authors...
This review introduces clinicians to the basic concepts of the biology of circulating tumour DNA (ctDNA), which is required to understand clinical use of ctDNA technology. We provide an overview of how new technology has improved the sensitivity of ctDNA detection over the last decade and the available techniques for ctDNA analysis including whole-genome sequencing (WGS), targeted cancer-associated gene panels, and methylation analysis. We discuss the most recent evidence from clinical trials fo...
Source
#1Eric Leung (Sunnybrook Health Sciences Centre)H-Index: 15
#2Kathy Han (Princess Margaret Cancer Centre)H-Index: 15
Last. Scott V. Bratman (Princess Margaret Cancer Centre)H-Index: 33
view all 10 authors...
Purpose: null Human papillomavirus (HPV) DNA offers a convenient circulating tumor DNA (ctDNA) marker for HPV-associated malignancies, but current methods, such as digital PCR (dPCR), provide insufficient accuracy for clinical applications in patients with low disease burden. We asked whether a next-generation sequencing approach, HPV sequencing (HPV-seq), could provide quantitative and qualitative assessment of HPV ctDNA in low disease burden settings. null Experimental Design: null We conducte...
Source
#1Lauren L. Ozimski (EPFL: École Polytechnique Fédérale de Lausanne)
#2David Gremmelspacher (EPFL: École Polytechnique Fédérale de Lausanne)
Last. Nicola Aceto (EPFL: École Polytechnique Fédérale de Lausanne)H-Index: 29
view all 3 authors...
SUMMARY null null Circulating tumor cells are metastatic precursors in several cancer types. Their biology and clinical utility are subject to numerous investigations, yet one aspect that is often neglected is their entanglement with the tumor microenvironment, namely the crosstalk with stromal and immune cells and their relationships with other tumor-derived components such as circulating tumor DNA and extracellular vesicles in circulation. We will focus our short review specifically on these a...
Source
#1Katelyn N Seale (UMB: University of Maryland, Baltimore)
#2Katherine Tkaczuk (UMB: University of Maryland, Baltimore)H-Index: 23
Breast cancer management has progressed immensely over the decades, but the disease is still a major source of morbidity and mortality worldwide. Even with enhanced imaging detection and tissue biopsy capabilities, disease can progress on an ineffective treatment before additional information is obtained through standard methods of response evaluation, including the RECIST 1.1 criteria, widely used for assessment of treatment response and benefit from therapy.6 Circulating biomarkers have the po...
Source
#1Anna-Lisa Doebley (UW: University of Washington)H-Index: 6
#2M. Ko (Fred Hutchinson Cancer Research Center)H-Index: 1
Last. Anna Hoge (Fred Hutchinson Cancer Research Center)H-Index: 1
view all 21 authors...
Cell-free DNA (cfDNA) has the potential to inform tumor subtype classification and help guide clinical precision oncology. Here we developed Griffin, a new method for profiling nucleosome protection and accessibility from cfDNA to study the phenotype of tumors using as low as 0.1x coverage whole genome sequencing (WGS) data. Griffin employs a novel GC correction procedure tailored to variable cfDNA fragment sizes, which improves the prediction of chromatin accessibility. Griffin achieved excelle...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.